Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07124000 · ClinicalTrials.gov registry record

DESTINY-PANTUMOUR04

A clinical trial of Head and Neck Cancer and Endometrial Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
100
Enrollment target
15
Study locations

NCT07124000 is a study of Head and Neck Cancer and Endometrial Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 100 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07124000, a study of Head and Neck Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
100 participants
Enrollment target
15
Study locations

Study Summary

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Conditions Studied

Head and Neck Cancer Endometrial Cancer Bladder Cancer Cervical Cancer Esophageal Cancer Liver Cancer Anal Cancer Gall Bladder Cancer Adenocarcinoma (NOS) Gastrointestinal Stromal Tumour

Interventions

  • DRUG Trastuzumab deruxtecan

Study Locations (15)

Florida

  • Research Site - Coral Springs
  • Research Site - Fort Myers
  • Research Site - Palm Harbor

North Carolina

  • Research Site - Durham
  • Research Site - Wilson

Ohio

  • Research Site - Canton
  • Research Site - Maumee

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Casa Grande

California

  • Research Site - San Diego

Colorado

  • Research Site - Aurora

Illinois

  • Research Site - O'Fallon

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-09-18
Est. Completion 2028-03-30

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07124000

The ClinicalTrials.gov registry entry for NCT07124000 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab deruxtecan is the first listed.

NCT07124000 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Florida, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT07124000 about?

NCT07124000 is a clinical study titled "DESTINY-PANTUMOUR04". This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world ...

What is the current status of trial NCT07124000?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-09-18. Estimated completion is 2028-03-30.

What conditions does trial NCT07124000 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Endometrial Cancer, Bladder Cancer, Cervical Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT07124000?

The interventions under investigation include: Trastuzumab deruxtecan (DRUG).

Who is sponsoring clinical trial NCT07124000?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07124000 being conducted?

This trial has 15 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.